Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2025-02-14 Major Shareholding Noti…
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification
2025-02-14 English
FORM 4
Director's Dealing
2025-01-08 English
FORM 3
Director's Dealing
2025-01-08 English
Director's Dealing 2025
Director's Dealing
2025-01-07 English
CIDARA THERAPEUTICS, INC. FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the resignation of a director, the separation of a chief medical officer, and the appointment of a new director, including compensation details. These are changes in the company's board of directors and senior management. There is no financial data or earnings information, so it is not an earnings release or financial report. The document fits the category of Board/Management Information (MANG) as it announces changes in the company's board and senior management.
2025-01-07 English
424B3
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) related to a resale registration of common stock shares and pre-funded warrants. It details a private placement transaction, the resale of shares by selling stockholders, and includes information about the company's business, management discussion and analysis, risk factors, and other disclosures typical of a securities offering document. The document is not an annual or quarterly report, earnings release, or management discussion standalone report. It is a capital markets filing related to financing activities and share registration for resale. Therefore, it fits best under the category Capital/Financing Update (CAP). The document length and content confirm it is a full prospectus, not a brief announcement or certification, supporting a high confidence classification.
2025-01-02 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.